Mustang Bio

Mustang Bio is a biotechnology company focused on developing next-generation cell and gene therapies to treat hematologic cancers, glioblastoma, and rare genetic diseases. The company aims to translate medical breakthroughs into potential cures, leveraging its proprietary CAR T manufacturing process and facility in Worcester, MA. This facility includes a fully equipped QC lab, a full research and PD lab, and four separate cleanrooms, forming part of the Mustang Advanced Research Site (MARS) capabilities. Mustang Bio has in-licensed clinical CAR T programs, including MB-106 for B-cell Non-Hodgkin Lymphoma, MB-101 for glioblastoma, and MB-109, which combines MB-101 CAR T cell therapy with MB-108 oncolytic virus. Additionally, C134 or MB-108 is a next-generation oncolytic herpes simplex virus for glioblastoma multiforme. The company adopts a strategic growth approach through targeted product acquisition, in-licensing, and co-development opportunities, and collaborates with leading academic institutions such as City of Hope and Mayo Clinic. Mustang Bio conducts robust and efficient clinical trials, with six ongoing trials involving their therapeutic candidates. The company received the Massachusetts Economic Impact Award for adding 56 new jobs since January 2020 and investing $2.5 million in a 6,000 square-foot expansion of their manufacturing facility. Committed to providing life-changing first-in-class cell and gene therapies, Mustang Bio focuses on CAR T cell therapy, which involves modifying patients’ T-cells to recognize specific cancers.